Blindness, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Leber Congenital Amaurosis, Leber Congenital Amaurosis 10, Neurologic Manifestations, Retinal Disease, Sensation Disorders, Vision Disorders
Conditions
Keywords
LCA10, CEP290, p.Cys998X, c.2991+1655A>G, Leber's Congenital Amaurosis, Antisense oligonucleotide, RNA therapy
Brief summary
Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety, tolerability, pharmacokinetic (PK), and efficacy data of QR-110.
Detailed description
Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Subjects will be given the opportunity to enroll into this extension study for continued dosing if available data support current and/or future benefits for the subject. The Investigator, in consultation and agreement with the Medical Monitor, will decide on enrollment of each individual subject, as well as on dosing of the first treated eye and treatment initiation of the contralateral eye. Continued subject treatment in this study is desirable, but cannot be guaranteed, since it will depend on the risks and benefit of further treatment on a case-by-case basis, as discussed and agreed upon with the Medical Monitor. The contralateral eye and the first treated eye will be injected 3 months apart. The injection interval of 3 months between both eyes will limit burden for the subjects, with a 3 month-visit frequency during the course of the study. This between-eye interval could be adapted if safety data are supportive, and for logistic reasons, and in agreement with the Medical Monitor. The same safety monitoring protocol and efficacy assessments will apply to both eyes. QR-110 will be administered via intravitreal (IVT) injection.
Interventions
DRUGQR-110
First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
Sponsors
Sepul Bio
Laboratoires Thea
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects who completed participation in the study PQ-110-001 and who may derive benefit from continued treatment with QR 110, as assessed by the Investigator, in consultation with the Medical Monitor * Persistence of detectable outer nuclear layer (ONL) in the area of the macula in the opinion of the Investigator, as determined by OCT. * Clear ocular media and adequate pupillary dilation to permit good quality retinal imaging, as assessed by the Investigator. * An adult (≥ 18 years) willing and able to provide informed consent for participation OR a minor (6 to \< 18 years) with a parent or legal guardian willing and able to provide written permission for the subject's participation prior to performing any study related procedures, and pediatric subjects able to provide age-appropriate assent for study participation. * Female subjects who have reached menarche and male subjects must either practice true abstinence in accordance with their preferred and usual lifestyle, or agree to use acceptable, highly effective methods of contraception for up to 3 months following their last dose QR-110. Acceptable methods of contraception are defined in the protocol. Women of non-childbearing potential may be included without the use of adequate birth control, provided they meet the criteria in the protocol.
Exclusion criteria
* Any contraindication to IVT injection according to the Investigator's clinical judgment and international guidelines (Avery 2014). * Safety issue during study PQ-110-001 that may compromise subject safety when continued dosing, as determined by the Investigator, and in consultation with the Medical Monitor. * Any ocular or systemic disease or condition (including medications and laboratory test abnormalities) that could compromise subject safety or interfere with assessment of efficacy and safety, as determined by the Investigator and in consultation with the Medical Monitor. * Pregnant or breast-feeding female.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Ocular AEs | 24 months | Frequency of ocular adverse events (AEs) |
| Frequency of Non-ocular AEs | 24 months | Frequency of non-ocular AEs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Photoreceptor Outer Segment Layer Thickness | 24 months | Change in photoreceptor outer segment layer thickness by Optical Coherence Tomography (OCT) |
| Change in OCI | 24 months | Change in Oculomotor Instability (OCI) |
| Change in FST Blue | 24 months | Change in Full-Field Stimulus Testing (FST) - blue stimuli |
| Change in FST Red | 24 months | Change in Full-Field Stimulus Testing (FST) - red stimuli |
| Change in VFQ-25 | 24 months | Change in Visual Function Questionnaire-25 (VFQ-25) score (adult subjects) |
| Change in BCVA in First Treated Eye | 24 months | Change in Best Corrected Visual Acuity (BCVA) in First Treated Eye |
| Change in PLR | 24 months | Change in Pupillary Light Reflex (PLR) (latency and amplitude) |
| Change in NIRAF | 24 months | Change in Near Infrared AutoFluorescence (NIRAF) |
| Change in BCVA in Treated Contralateral Eye | 24 months | Change in Best Corrected Visual Acuity (BCVA) in Treated Contralateral Eye |
| Change in BCVA in Non-Treated Contralateral Eye | 24 months | Change in Best Corrected Visual Acuity (BCVA) in Non-Treated Contralateral Eye |
| Change in CVAQ | 24 months | Change in Cardiff Visual Ability Questionnaire for Children (CVAQC) score (pediatric subjects) |
| Change in Mobility Course Score | 24 months | Change in Mobility course score |
Countries
Belgium, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Drug QR-110 First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
QR-110: First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration | 9 |
| Total | 9 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Sponsor Decision | 1 |
Baseline characteristics
| Characteristic | Drug QR-110 |
|---|---|
| Age, Customized <18 years | 3 Participants |
| Age, Customized >= 18 Years | 6 Participants |
| Age, Customized Age (Mean) | 24.7 Years STANDARD_DEVIATION 12.7 |
| Age, Customized Age (Median) | 23.0 Years |
| BMI (Mean) | 23.02 kg/m2 STANDARD_DEVIATION 5.2 |
| BMI (Median) | 21.89 kg/m2 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 9 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Genotype Compound Heterozygous | 8 Participants |
| Genotype Homozygous | 1 Participants |
| Height (Mean) | 164.9 cm STANDARD_DEVIATION 11.8 |
| Height (Median) | 166.3 cm |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 9 Participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 5 Participants |
| Weight (Mean) | 64.26 kg STANDARD_DEVIATION 23.19 |
| Weight (Median) | 61.55 kg |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 9 |
| other Total, other adverse events | 8 / 9 |
| serious Total, serious adverse events | 1 / 9 |
Outcome results
Primary
Frequency of Non-ocular AEs
Frequency of non-ocular AEs
Time frame: 24 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Drug QR-110 | Frequency of Non-ocular AEs | 6 Participants |
Primary
Frequency of Ocular AEs
Frequency of ocular adverse events (AEs)
Time frame: 24 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Drug QR-110 | Frequency of Ocular AEs | 7 Participants |
Secondary
Change in BCVA in First Treated Eye
Change in Best Corrected Visual Acuity (BCVA) in First Treated Eye
Time frame: 24 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Drug QR-110 | Change in BCVA in First Treated Eye | 0.03 logMAR | Standard Deviation 0.17 |
Secondary
Change in BCVA in Non-Treated Contralateral Eye
Change in Best Corrected Visual Acuity (BCVA) in Non-Treated Contralateral Eye
Time frame: 24 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Drug QR-110 | Change in BCVA in Non-Treated Contralateral Eye | 0.05 logMAR | Standard Deviation 0.21 |
Secondary
Change in BCVA in Treated Contralateral Eye
Change in Best Corrected Visual Acuity (BCVA) in Treated Contralateral Eye
Time frame: 24 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Drug QR-110 | Change in BCVA in Treated Contralateral Eye | -0.11 logMAR | Standard Deviation 0.23 |
Secondary
Change in CVAQ
Change in Cardiff Visual Ability Questionnaire for Children (CVAQC) score (pediatric subjects)
Time frame: 24 months
Secondary
Change in FST Blue
Change in Full-Field Stimulus Testing (FST) - blue stimuli
Time frame: 24 months
Secondary
Change in FST Red
Change in Full-Field Stimulus Testing (FST) - red stimuli
Time frame: 24 months
Secondary
Change in Mobility Course Score
Change in Mobility course score
Time frame: 24 months
Secondary
Change in NIRAF
Change in Near Infrared AutoFluorescence (NIRAF)
Time frame: 24 months
Secondary
Change in OCI
Change in Oculomotor Instability (OCI)
Time frame: 24 months
Secondary
Change in Photoreceptor Outer Segment Layer Thickness
Change in photoreceptor outer segment layer thickness by Optical Coherence Tomography (OCT)
Time frame: 24 months
Secondary
Change in PLR
Change in Pupillary Light Reflex (PLR) (latency and amplitude)
Time frame: 24 months
Secondary
Change in VFQ-25
Change in Visual Function Questionnaire-25 (VFQ-25) score (adult subjects)
Time frame: 24 months